Please assess the completion status of the following clinical trial:

Trial Title: Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Child born at less than or equal to 29 completed weeks' gestation;~2. Child between 18 months, 0 days and 38 months, 30 days old chronological age;~3. Child admitted to NICU and/or had a Neonatology Clinic follow up visit scheduled.~4. Child showing some autistic symptoms;~5. Child between the 5th and 95th percentiles (per WHO growth chart) for weight at his/her most recent hospital visit;~6. English spoken in the home, demonstrate ability to communicate in English well-enough to understand study, informed consent, and study questionnaires; and~7. Have informed consent on file.~Exclusion Criteria:~1. Consume LCPUFA supplement drops, chews, powders, Pediasure, or fatty fish more than 2x per week;~2. Unable to tolerate venipuncture;~3. Any major malformation that would preclude participation;~4. Cerebral Palsy (quadriparesis only);~5. Deafness;~6. Blindness;~7. Bleeding disorder;~8. Type I diabetes;~9. Fragile X Syndrome, Rett Syndrome, Angelman Syndrome, Tuberous Sclerosis;~10. Non febrile seizure in the last month without a clear and resolved etiology;~11. Feeding problem that may inhibit full participation;~12. Known fish allergy;~13. Known canola/rapeseed allergy or sensitivity; or~14. Recorded score of \<70 on Bayley Cognitive Section within the past year.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 39 Months
- Healthy Volunteers: f

Study Arms:
- LCPUFA Oil Supplement (Type: EXPERIMENTAL): EPA + DHA + GLA + OA oil supplement
- Canola Oil Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).